Ocugen to Participate in a Virtual Fireside Chat at the Chardan Genetic Medicines Conference

September 29, 2020 at 7:35 AM EDT

MALVERN, Pa., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will participate in a Virtual Fireside Chat during the Chardan Genetic Medicines Conference on October 6th at 9 a.m.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder along with Dr. Mohamed Genead, M.D., Acting Chief Medical Officer, will discuss the advantages of Ocugen’s Modifier Gene Therapy Platform and provide an overview of the preclinical results using NR2E3 as a genetic modifier that was published earlier this year in Nature Gene Therapy. In addition, Drs. Musunuri and Genead will discuss planning around the initiation of their Phase 1/2a studies in 2021 for OCU400 including an update on scale-up manufacturing of clinical supplies with CanSinoBIO. OCU400 is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases. They will also discuss other business progress including OCU200 program.

Presentation Details:

Conference: Chardan Genetic Medicines Conference
Format: Fireside Chat
Date: Tuesday, October 6, 2020
Time: 9:00 AM (Eastern Time)
Webcast Link: https://wsw.com/webcast/chard6/ocgn/1842984

The Chardan Genetic Medicines Conference will take place on October 5-6.

About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Corporate Contact:
Ocugen, Inc.
Sanjay Subramanian
Chief Financial Officer
ir@ocugen.com

Media Contact:
LaVoieHealthScience
Katie Gallagher
kgallagher@lavoiehealthscience.com
+1 617-792-3937